Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Henlius BiotechHKSE:02696 -1.10%67 Piotroski F-Score is 6 as of Aug. 16, 2026, which is at its 10-year median of 6.00. GuruFocus rates HKSE:02696 with a GF Score™ of 67/100 and a GF Value™ of HK$30.91 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,329 Biotechnology companies, Shanghai Henlius Biotech ranks better than 91.72% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Shanghai Henlius Biotech has an F-score of 6 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Shanghai Henlius Biotech's Piotroski F-Score or its related term are showing as below:
HKSE:02696'
s Piotroski F-Score Range Over the Past 10 Years
Min: 4 Med: 6 Max: 7
Current: 6
During the past 9 years, the highest Piotroski F-Score of Shanghai Henlius Biotech was 7. The lowest was 4. And the median was 6.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Shanghai Henlius Biotech Piotroski F-Score Related Terms
Shanghai Henlius Biotech Piotroski F-Score Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02696 vs VRTX, REGN, RVMD: Piotroski F-Score Comparison
For the Biotechnology subindustry, Shanghai Henlius Biotech's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Henlius Biotech Piotroski F-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanghai Henlius Biotech's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Shanghai Henlius Biotech's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Shanghai Henlius Biotech's current Net Income (TTM) was 914.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Shanghai Henlius Biotech's current Cash Flow from Operations (TTM) was 1,442.
==> Positive ==> Score 1.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Shanghai Henlius Biotech's return on assets of this year was 0.08074946. Shanghai Henlius Biotech's return on assets of last year was 0.08086848.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Shanghai Henlius Biotech's gearing of this year was 0.1194873. Shanghai Henlius Biotech's gearing of last year was 0.1049663.
==> Last year is lower than this year ==> Score 0.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Shanghai Henlius Biotech's current ratio of this year was 0.70555321. Shanghai Henlius Biotech's current ratio of last year was 0.49911085.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Shanghai Henlius Biotech's number of shares in issue this year was 545.933. Shanghai Henlius Biotech's number of shares in issue last year was 543.495.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Shanghai Henlius Biotech's gross margin of this year was 0.74771053. Shanghai Henlius Biotech's gross margin of last year was 0.73101576.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Shanghai Henlius Biotech's asset turnover of this year was 0.65090596. Shanghai Henlius Biotech's asset turnover of last year was 0.56422223.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
0
+
1
+
0
+
1
+
0
+
1
+
1
=
6
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Shanghai Henlius Biotech has an F-score of 6 indicating the company's financial situation is typical for a stable company.
Shanghai Henlius Biotech (HKSE:02696) has a Piotroski F-Score of 6 as of Aug. 16, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Shanghai Henlius Biotech and its competitors. This is near median its historical median of 6.00. Over the past decade, Shanghai Henlius Biotech's Piotroski F-Score has ranged from 4.00 to 7.00. According to the industry distribution chart, Shanghai Henlius Biotech ranks #110 out of 1329 companies in the Biotechnology industry, placing it in the top 8.3%.
Is Shanghai Henlius Biotech's Piotroski F-Score too high?
Shanghai Henlius Biotech's current Piotroski F-Score of 6 is near median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 7.00. The Biotechnology industry median Piotroski F-Score is 3.00. Shanghai Henlius Biotech's value of 6 is 100% above this industry median. Based on the distribution chart, Shanghai Henlius Biotech ranks #110 out of 1329 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Shanghai Henlius Biotech has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Henlius Biotech's Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Henlius Biotech ranks #110 out of 1329 companies for Piotroski F-Score. This places Shanghai Henlius Biotech in the top 8% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 3.00. Shanghai Henlius Biotech's value of 6 is 100% above this benchmark. Historically, Shanghai Henlius Biotech's own Piotroski F-Score has ranged from 4.00 to 7.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 3.00, Shanghai Henlius Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,329 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Henlius Biotech's current Piotroski F-Score of 6 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Shanghai Henlius Biotech and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Henlius Biotech's current Piotroski F-Score is 6, which is near median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Henlius Biotech stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Henlius Biotech (HKSE:02696) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$30.91, compared to a current price of HK$67.30 — trading 117.7% above its estimated fair value. The current Piotroski F-Score is 6, which is near median its 10-year median of 6.00 and 100% above the Biotechnology industry median of 3.00. Shanghai Henlius Biotech's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Shanghai Henlius Biotech (HKSE:02696), the current Piotroski F-Score is 6 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Henlius Biotech (HKSE:02696) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Henlius Biotech stock appears to be overvalued.
The current stock price of HK$67.30 is trading 117.7% above its estimated GF Value™ of HK$30.91.
GuruFocus considers Shanghai Henlius Biotech to be Significantly Overvalued.
Key valuation signals for HKSE:02696:
Piotroski F-Score: 6 (near median its 10-year median of 6.00)
GF Value™: HK$30.91 vs. price of HK$67.30 (117.7% above fair value)
Industry Position: 100% above the Biotechnology median (#110 of 1329)
No single metric tells the full story. See the HKSE:02696 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China, Asia Pacific (excluding Mainland China), North America, South America, Oceania, and Europe. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.
67GF Score
Get the complete analysis for HKSE:02696
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02696 has been successfully added to your 
